MHRA's CE Mark Recognition: What Indefinite Alignment Really Means

The MHRA's newly launched consultation on indefinite recognition of CE-marked medical devices represents the clearest signal yet that the UK's post-Brexit regulatory divergence strategy may be shifting from ideology to pragmatism. After years of uncertainty around UKCA marking deadlines and transitional arrangements, this consultation asks a deceptively simple question: should Great Britain continue to accept EU-certified devices indefinitely, or proceed with full regulatory separation? For manufacturers juggling dual compliance strategies and notified body relationships across two jurisdictions, the answer will fundamentally reshape market access planning for the next decade.

The Context Behind the Consultation

Since Brexit, the UK medical device regulatory landscape has existed in a state of managed ambiguity. The original plan called for mandatory UKCA marking to replace CE marks in Great Britain by July 2023, later extended to July 2024, then again to July 2025, and most recently pushed to July 2028. Each extension reflected the same underlying tension: the desire for regulatory sovereignty versus the economic and practical realities of maintaining two parallel compliance regimes for a market representing roughly 3% of the global MedTech opportunity.

The MHRA's consultation now formally acknowledges what many in industry have long suspected—that indefinite recognition of CE marking may be the most viable long-term approach. The consultation document presents several options, but the headline proposal involves continuing to accept devices certified under EU MDR and IVDR by EU-recognised notified bodies, potentially without a sunset clause. This would represent a fundamental departure from the trajectory established immediately post-Brexit, when regulatory independence was framed as both inevitable and desirable.

What makes this particularly significant is the timing. The consultation arrives as manufacturers are making final decisions about their 2025-2026 regulatory roadmaps. Many have already invested substantially in dual pathways: securing UK Responsible Persons, engaging with UK Approved Bodies for UKCA certification, and maintaining separate technical documentation streams. Others adopted a wait-and-see approach, gambling that continued extensions would eventually lead to permanent recognition. This consultation suggests the latter group may have read the political winds more accurately than those who invested early in full separation.

The Notified Body Capacity Reality

Beneath the surface of this policy discussion lies a less-discussed but critical constraint: notified body and approved body capacity. The EU is still working through the massive backlog created by MDR and IVDR transitions, with many manufacturers still awaiting certificate transfers years after the regulations took full effect. The UK, meanwhile, has a limited number of approved bodies capable of conducting conformity assessments under UKCA requirements.

If the UK were to mandate full UKCA certification for all devices currently accessing the market via CE marks, the system would face immediate gridlock. UK approved bodies simply lack the bandwidth to recertify the tens of thousands of device types currently sold in Great Britain. This isn't a theoretical bottleneck—it's an arithmetical certainty. The MHRA understands this, which is why indefinite recognition isn't just a political olive branch to industry; it's an operational necessity for maintaining device availability in the NHS and private healthcare sector.

This reality creates an interesting dynamic for manufacturers. Those who pursued early UKCA certification may find themselves maintaining dual certifications not because of regulatory requirement, but because of commercial positioning or supply chain considerations. Meanwhile, manufacturers serving primarily EU markets with incidental UK sales can likely continue treating Great Britain as an extension of their CE mark strategy, at least for medical devices and IVDs covered by the recognition policy.

What Indefinite Recognition Doesn't Mean

Before regulatory teams breathe too deep a sigh of relief, it's critical to understand what this consultation doesn't signal. First, indefinite CE mark recognition doesn't mean regulatory alignment. The MHRA has repeatedly stated its intention to maintain independent decision-making on device safety issues, post-market surveillance requirements, and regulatory guidance. We've already seen divergence in areas like software as a medical device classification, vigilance reporting timelines, and clinical evaluation expectations.

Second, recognition of CE marking doesn't eliminate other UK-specific requirements. Devices placed on the Great Britain market still require UK Responsible Persons, registration in the MHRA database, and compliance with UK-specific labeling and language requirements. The administrative burden doesn't disappear; it merely shifts from pre-market certification to post-market compliance management.

Third, this consultation applies to Great Britain only. Northern Ireland continues to follow EU rules under the Windsor Framework, creating a three-way regulatory split: EU proper, Northern Ireland, and Great Britain. Manufacturers serving all three markets must still navigate this complexity, though indefinite CE mark recognition in GB at least reduces it from a three-certification to a two-certification challenge for most device types.

Finally, 'indefinite' doesn't mean 'permanent' or 'irrevocable.' Future governments could reverse this policy, particularly if political winds shift back toward regulatory divergence. Manufacturers building long-term strategies should consider indefinite recognition as the current policy direction, not a guaranteed future state. Regulatory flexibility and the ability to pivot remain valuable organizational capabilities.

What This Means for Your Regulatory Strategy

For regulatory affairs teams, this consultation creates both clarity and complexity. The clearest implication is that aggressive timelines for mandatory UKCA implementation are increasingly unlikely. Teams that have been operating in crisis mode, racing to secure UK approved body capacity before a hard deadline, can likely shift to a more measured approach. This doesn't mean abandoning UKCA plans entirely—some devices, particularly higher-risk implantables or novel technologies where differentiated UK market positioning matters, may still benefit from UKCA certification. But it does mean the decision becomes strategic rather than compulsory.

The consultation also underscores the importance of maintaining robust EU MDR and IVDR compliance. If CE mark recognition becomes the permanent pathway for GB market access, your notified body relationship and EU technical documentation become even more critical. Any gaps in EU compliance don't just affect EU market access—they now potentially impact UK access indefinitely. This makes notified body selection, audit performance, and proactive communication with your conformity assessment partners more important than ever.

For companies currently deciding between UKCA and CE mark strategies, the risk calculation has shifted. Previously, the risk was investing in CE-only strategies and facing sudden UK market exclusion. Now, the risk is investing heavily in UKCA infrastructure that may become commercially unnecessary. The optimal approach for most manufacturers likely involves maintaining CE mark compliance as the primary pathway while keeping UKCA as an option for specific strategic situations—product differentiators, UK-first launches, or devices where UK-specific clinical evidence creates competitive advantages.

Responding to the Consultation

The MHRA consultation represents a genuine opportunity for industry input to shape policy. Unlike some consultations that feel like rubber-stamping exercises for predetermined decisions, this one arrives at a genuine policy crossroads. The MHRA appears to be genuinely weighing options, and well-reasoned industry responses could influence the final framework.

Effective consultation responses should move beyond simply advocating for indefinite recognition and engage with the nuances. What safeguards should accompany recognition to address diverging safety standards? How should the MHRA maintain oversight of devices certified by EU notified bodies? What mechanisms should exist for addressing devices where UK and EU regulatory views diverge? Thoughtful responses to these questions will carry more weight than simple lobbying for the status quo.

Trade associations and professional bodies will submit collective responses, but individual manufacturer perspectives add valuable texture, particularly around operational realities, patient access implications, and innovation impacts. If your organization has experienced specific challenges or benefits from the current transitional arrangements, documenting these with concrete examples strengthens the evidence base for policymaking.

Key Takeaways

• The MHRA consultation on indefinite CE mark recognition signals a likely long-term shift toward pragmatic alignment rather than regulatory divergence, but 'indefinite' doesn't mean irrevocable or without UK-specific requirements
• Notified body capacity constraints make full UKCA transition operationally unfeasible in the near term, meaning indefinite recognition isn't just policy preference but practical necessity for maintaining device availability
• Regulatory teams should maintain robust EU MDR/IVDR compliance as the primary GB market access pathway while treating UKCA as a strategic option for specific competitive situations rather than a universal requirement
• The consultation represents a genuine opportunity for industry input—well-reasoned responses addressing implementation details and safeguards will be more influential than simple advocacy for continued recognition

The next few months will clarify whether the UK's medical device regulatory future involves permanent alignment via CE mark recognition or a more complex hybrid model. Either way, the era of imminent mandatory UKCA transition appears to be ending, replaced by a more stable framework where strategic choices replace regulatory mandates. For regulatory affairs teams, this means shifting from crisis management to thoughtful strategy—understanding not just what's required, but what's optimal for your specific products, markets, and competitive positioning. As this policy landscape crystallizes, having regulatory partners who understand both the technical requirements and the strategic implications becomes increasingly valuable.